Merck & Co showed strong performance in Q2 2011, surpassing sales expectations and maintaining robust growth across key brands and new product launches such as VICTRELIS and Simcere partnership in China. However, the stock might face short-term pressure due to significant restructuring charges and potential concerns over revenue impacts from a shifting focus to lower-cost operations and substantial cost-cutting measures over the next few years.
[0]
        